South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

Gynecologic Oncology, an esteemed journal published by Academic Press Inc Elsevier Science, stands at the forefront of research in the domains of Obstetrics and Gynecology and Oncology. With an exceptional track record dating from 1972 to 2024, this journal has established itself as a vital resource for scholars and practitioners alike, boasting a remarkable Q1 ranking in both fields as of 2023. Gynecologic Oncology not only ranks #13 out of 209 in Obstetrics and Gynecology and #72 out of 404 in Oncology but also operates within the top percentiles of academic influence, with a 94th percentile in Obstetrics and Gynecology and an 82nd percentile in Oncology on Scopus. Although the journal does not currently offer open access, it remains crucial for disseminating original research, reviews, and advances in the management and treatment of gynecological cancers. Researchers and health professionals will find this journal indispensable for staying informed on the latest advancements and breakthroughs in this vital area of medicine, fostering a deeper understanding and potentially transforming patient care practices.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

The European Journal of Surgical Oncology (EJSO), published by Elsevier Science Ltd, stands as a leading international journal dedicated to the field of surgical oncology. With an ISSN of 0748-7983 and an E-ISSN of 1532-2157, EJSO has been a key resource for researchers and practitioners since its inception in 1985, covering a wide spectrum of topics in advanced surgical techniques, oncology practices, and multidisciplinary approaches to cancer treatment. The journal boasts impressive rankings, being classified in the Q1 quartile for Medicine (Miscellaneous) and Surgery, and Q2 in Oncology for 2023, reflecting its high impact within the scientific community, with a Scopus ranking of #36/551 in Medicine and Surgery, placing it in the 93rd percentile. Although it does not currently offer Open Access options, EJSO remains committed to advancing the field through reliable research and innovative surgical methodologies. Its ongoing contributions are invaluable for those engaged in the continuous improvement of cancer treatment and management.

Actas Urologicas Espanolas is a prestigious journal published by Elsevier España, dedicated to the field of Urology. Established in 1977, this journal has significantly contributed to advancing knowledge and research in urological medicine and surgery, spanning a comprehensive scope that includes clinical studies, surgical techniques, and the latest innovations in the treatment of urological diseases. With an impact factor reflecting its critical role in the academic community, it is ranked Q3 in the Urology category as of 2023, placing it amongst the valuable resources for professionals and researchers. The journal is indexed under Scopus, achieving a commendable rank of #70 out of 120 in the Medicine-Urology category, situating it within the 42nd percentile. As a significant platform for sharing advancements and findings, it encourages submissions that enhance urological care and improve patient outcomes. Although not an Open Access journal, the publication remains vital for those looking to stay updated on the latest developments in urology. For more details, visit their office located at CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN.

Surgical Oncology-Oxford is a prestigious academic journal published by Elsevier Science Ltd, dedicated to advancing the field of surgical oncology. Since its establishment in 1992, the journal has provided a vital platform for disseminating cutting-edge research, clinical advancements, and innovative surgical techniques. With a focus on both surgery and oncology, the journal is ranked in the Q2 category in Surgery and Q3 in Oncology for 2023, reflecting its commitment to quality and impactful contributions. It ranks #107 out of 551 in Medicine_Surgery and #184 out of 404 in Medicine_Oncology as per Scopus metrics, illustrating its significant role in the academic landscape. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that only the highest quality research is published. By examining the latest surgical methodologies and oncological insights, Surgical Oncology-Oxford plays a crucial role in enhancing clinical practice and improving patient outcomes, making it an essential resource for researchers, healthcare professionals, and students aiming to stay at the forefront of the field.

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.